These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

652 related items for PubMed ID: 21362108

  • 1. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
    Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P, Sativex Spasticity Study Group.
    Eur J Neurol; 2011 Sep; 18(9):1122-31. PubMed ID: 21362108
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
    Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O'Leary C, Ratcliffe S, Nováková I, Zapletalova O, Piková J, Ambler Z.
    Neurol Res; 2010 Jun; 32(5):451-9. PubMed ID: 20307378
    [Abstract] [Full Text] [Related]

  • 3. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P.
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [Abstract] [Full Text] [Related]

  • 4. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
    Wade DT, Collin C, Stott C, Duncombe P.
    Mult Scler; 2010 Jun; 16(6):707-14. PubMed ID: 20558502
    [Abstract] [Full Text] [Related]

  • 5. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
    Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R.
    Mult Scler; 2012 Feb; 18(2):219-28. PubMed ID: 21878454
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.
    Bethoux FA, Farrell R, Checketts D, Sahr N, Berwaerts J, Alexander JK, Skobieranda F.
    Mult Scler Relat Disord; 2024 Sep; 89():105740. PubMed ID: 39106541
    [Abstract] [Full Text] [Related]

  • 7. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
    Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [Abstract] [Full Text] [Related]

  • 8. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P, Henze T, Zettl UK.
    Eur Neurol; 2014 Feb; 71(5-6):271-9. PubMed ID: 24525548
    [Abstract] [Full Text] [Related]

  • 9. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group.
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
    Nicholas J, Lublin F, Klineova S, Berwaerts J, Chinnapongse R, Checketts D, Javaid S, Steinerman JR.
    Mult Scler Relat Disord; 2023 Jul; 75():104745. PubMed ID: 37209500
    [Abstract] [Full Text] [Related]

  • 11. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.
    Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ.
    Mult Scler; 2010 Nov; 16(11):1349-59. PubMed ID: 20829244
    [Abstract] [Full Text] [Related]

  • 12. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG, Henze T, Essner U, Trompke C, Vila Silván C.
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [Abstract] [Full Text] [Related]

  • 13. Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in Austria.
    Guger M, Hatschenberger R, Leutmezer F.
    Brain Behav; 2023 Apr; 13(4):e2947. PubMed ID: 36934456
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G, CANALS Study Group.
    Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
    [Abstract] [Full Text] [Related]

  • 15. Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.
    Kleiner D, Horváth IL, Bunduc S, Gergő D, Lugosi K, Fehérvári P, Hegyi P, Csupor D.
    Curr Neuropharmacol; 2023 Feb; 21(12):2505-2515. PubMed ID: 37519000
    [Abstract] [Full Text] [Related]

  • 16. Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.
    Koehler J, Amato MP, Oreja-Guevara C, Lycke J.
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):61-6. PubMed ID: 24289846
    [Abstract] [Full Text] [Related]

  • 17. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.
    Eur Neurol; 2016 Dec; 75(5-6):236-43. PubMed ID: 27160412
    [Abstract] [Full Text] [Related]

  • 18. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G, Donato F, Turri M, Deotto L, Teatini F, Moretto G, Erro R.
    J Neurol Sci; 2016 Nov 15; 370():263-268. PubMed ID: 27772772
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of memantine as treatment for spasticity in multiple sclerosis.
    Mehta LR, McDermott MP, Goodman AD, Schwid SR.
    Mult Scler; 2010 Feb 15; 16(2):248-51. PubMed ID: 20028712
    [Abstract] [Full Text] [Related]

  • 20. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M.
    Mult Scler; 2004 Aug 15; 10(4):417-24. PubMed ID: 15327040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.